Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. - Wikidata - awgldk - TriplyDB

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

http://www.wikidata.org/entity/Q40600194

about

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis Imiglucerase in the treatment of Gaucher disease: a history and perspective Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.Enzyme replacement therapy for Anderson-Fabry disease Pain management strategies for neuropathic pain in Fabry disease--a systematic review Clinical studies in lysosomal storage diseases: Past, present, and future Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability Catalytic mechanism of human alpha-galactosidase Interconversion of the Specificities of Human Lysosomal Enzymes Associated with Fabry and Schindler Diseases The Molecular Basis of Pharmacological Chaperoning in Human α-Galactosidase Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy Development of a highly sensitive immuno-PCR assay for the measurement of α-galactosidase A protein levels in serum and plasma Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells Female with Fabry Disease Unknowingly Donates Affected Kidney to Sister: A Call for Pre-transplant Genetic Testing.Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data Fabry disease in latin america: data from the fabry registry.Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.Fabry disease and the skin: data from FOS, the Fabry outcome survey.Arrhythmias in Fabry cardiomyopathy.Angiokeratomas of Fabry successfully treated with intense pulsed light.Fabry's disease discovered with chance urinary mulberry cells: a case report.Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?

P2860

Q21004071-2AD16671-A685-4568-8513-55FBC1ECE546 Q21202889-00170239-04CB-409F-9E84-269F58E9E517 Q21261394-18FDE616-0A1E-45AE-83A6-9871B5B53D5A Q24200877-7C0FE226-0058-4CE5-9E48-5895197A501D Q24235483-CB504332-36E7-4D8A-96D3-74FA5CAEA5B3 Q24533551-E99A4738-7203-4313-BA2D-E617F3A36A04 Q24597943-A024C907-59CE-44E2-8423-891B647CAE80 Q24631426-FE53B3B5-3C41-4A6D-87CA-727FFBF88E0B Q24650910-6D658A78-5A08-42F1-8A84-388E44531DE9 Q24794000-080B1225-2F18-4CDA-91EE-5A2AA83956B0 Q26471010-2A7B861B-6D5F-4F10-8CB7-A56A22D1A631 Q26766561-3C88E207-D82F-4B71-9E65-C35F8C5F8FC0 Q27025186-BF1A263A-CD92-44D7-AC37-236BA78E3556 Q27654912-413F287B-9A55-4EBC-A9FB-F7644368771D Q27658332-E5D1CCFF-6F5C-40AF-AC50-B29CDF205EF6 Q27661323-8A99E232-49DB-4751-87E1-39ED48AF4689 Q27676392-444E0CF1-7017-4D5B-A79F-3A1BFDA26631 Q28075470-7BDD7C94-6761-4260-AAB2-C1A583FD8D1A Q28250905-B0936502-1117-4C0E-8051-44E8F26AC6D6 Q28258072-F8A95A7F-298A-44DB-896B-98BD3E43E0A4 Q28258153-DD48A7BA-8084-4D6D-B00F-7129CD18180F Q28477142-978E718D-301D-464F-9B04-BCAFBD075914 Q28478586-24C88051-6D4A-40AF-B060-731E42B547B6 Q28535053-9B90E285-1FF3-4E68-98D8-DC423B18950B Q28727768-0B7C4C4D-D928-4E02-90E8-D01781287149 Q30422379-2C74D70B-73C1-4065-86F3-4323FD98DE54 Q30458149-75F31E42-BF73-470F-822A-E581BE1DA627 Q30476504-35A13DB5-A9B8-462D-9500-D8E256851172 Q30497736-09F0472C-16DD-4944-BF0A-F307183BC0F2 Q30578294-41CB9B6F-9B90-42B2-AD9B-76E813486FD4 Q30592389-F8AED627-4D2C-40A7-9B80-67012BD7D182 Q30632134-2DFA17AB-ED77-4C9F-8DF1-D185BAFA3E93 Q30873303-D0A76938-581C-45E2-8D11-7B3E96ADD825 Q31060724-92CC7A15-0AC7-4522-8894-C42B3BC35953 Q31116015-1E88F8D6-A6F1-4AC4-9657-162B2AD79631 Q33161649-C8706C72-EB3B-4E40-A5A6-62853AA1484B Q33373387-5219E761-1E3D-4922-B6DE-39E8B38974B6 Q33628288-729EEB58-1523-4512-84AA-7CD68AEEAA9C Q33637062-0F56C313-A2C3-4E51-830B-10A1ADFC2674 Q33645550-1C091B70-303D-4FEA-8F1E-2D65E5044EAB

P2860

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

http://www.wikidata.org/entity/Q40600194

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

2001年论文

@zh

2001年论文

@zh-cn

name

Safety and efficacy of recombi ...... nt therapy in Fabry's disease.

@en

type

label

Safety and efficacy of recombi ...... nt therapy in Fabry's disease.

@en

prefLabel

Safety and efficacy of recombi ...... nt therapy in Fabry's disease.

@en

P1433

Q40600194-7B23854F-4A9B-4F4E-A3BE-7851D279DC29

P1476

Q40600194-168B26AF-4A51-49BA-9BDA-71D788FF008B

P2093

Q40600194-27DE5480-2AF6-4D6C-B240-E06D83AF9F18

Q40600194-46C3BCB2-BE43-4EBD-881C-13ED5A88A05B

Q40600194-4E6B05C2-5BDE-4703-B236-95C87B86B557

Q40600194-6242F117-7AB6-43FD-83DD-135C07EB84F6

Q40600194-71688F18-DE81-4F69-AB48-25CE3DAAEF16

Q40600194-79242996-937F-4C17-B383-BB301BF5F39E

Q40600194-907440AB-1356-46D4-BE6C-E66D4CBD1B61

Q40600194-90BE5323-0C64-4E6E-A9ED-7D6E93647BEC

Q40600194-DDCE39AB-E87A-49AB-AD82-3DD0D74BB120

Q40600194-E921EA14-D1E9-4E61-BC15-2D05DC70EE1D

P304

Q40600194-A48CE623-FA91-4F3A-846C-396535C973CF

P31

Q40600194-E1144BD8-D17B-4134-882B-5E6204E23938

P356

Q40600194-771EBA2A-C41C-452A-BB59-B12FAC66E7AD

P407

Q40600194-BDBC9F9A-5259-424C-BE0A-41E02C17BF26

P433

Q40600194-B911C590-2D7E-48E8-910B-FF82904868D8

P478

Q40600194-EFF4753A-BEE5-4184-9CFB-52344679579D

P577

Q40600194-3CA4B017-DA03-4FE9-B33D-18D5D4F99C6F

P698

Q40600194-7DD1D6D3-3A45-453D-B09A-F867D8A5E533

P356

NEJM200107053450102

P1433

The New England Journal of Medicine

P1476

Safety and efficacy of recombi ...... nt therapy in Fabry's disease.

@en

P2093

C M Eng

http://www.w3.org/2001/XMLSchema#string

D P Germain

http://www.w3.org/2001/XMLSchema#string

G E Linthorst

http://www.w3.org/2001/XMLSchema#string

International Collaborative Fabry Disease Study Group

http://www.w3.org/2001/XMLSchema#string

L Caplan

http://www.w3.org/2001/XMLSchema#string

N Guffon

http://www.w3.org/2001/XMLSchema#string

P Lee

http://www.w3.org/2001/XMLSchema#string

R J Desnick

http://www.w3.org/2001/XMLSchema#string

S Waldek

http://www.w3.org/2001/XMLSchema#string

W R Wilcox

http://www.w3.org/2001/XMLSchema#string

P304

9-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM200107053450102

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

345

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11439963

http://www.w3.org/2001/XMLSchema#string